Abstract
Aim: Simeprevir (SMV) is a protease inhibitor which demonstrates good tolerability and high antiviral response in patients with hepatitis C. The clinical outcomes of triple therapy using simeprevir, pegylated interferon and ribavirin (SMV/PEG IFN/RBV) for recurrent hepatitis C after living donor liver transplantation (LDLT) have not been well reported. In this study, we assessed the outcomes of patients with recurrent hepatitis C (genotype 1) after LDLT who received triple therapy at our hospital. Methods: SMV/PEG IFN/RBV was administrated for 12 weeks (triple therapy), followed by another 12 weeks or extended period of PEG IFN/RBV (dual therapy). Virological response, interaction with calcineurin inhibitors and adverse events were retrospectively analyzed. Results: Ten patients with recurrent hepatitis C after LDLT completed 12 weeks of triple therapy. Nine patients achieved rapid or early virological response, and one patient was a non-responder. The nine responders received subsequent dual therapy, and the duration of dual therapy was extended (24 to 36 weeks) in five cases. Although one patient was in relapse 8 weeks after completing the standard duration (12 weeks) of dual therapy, eight patients achieved sustained virological response for 12 weeks (SVR12). The SVR12 rate was 80%. Trough levels of calcineurin inhibitor did not show marked changes after introduction of SMV in all cases. There were no major adverse events associated with SMV. Conclusion: SMV treatment may be a safe and effective option for recurrent hepatitis C after LDLT.
| Original language | English |
|---|---|
| Pages (from-to) | 1118-1128 |
| Number of pages | 11 |
| Journal | Hepatology Research |
| Volume | 46 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 2016 Oct 1 |
Fingerprint
Keywords
- calcineurin inhibitor
- direct-acting antiviral agent
- living donor liver transplantation
- recurrent hepatitis C
- simeprevir
- virological response
ASJC Scopus subject areas
- Hepatology
- Infectious Diseases
Cite this
Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. / Shinoda, Masahiro; Ebinuma, Hirotoshi; Itano, Osamu; Yamagishi, Yoshiyuki; Obara, Hideaki; Kitago, Minoru; Nakamoto, Nobuhiro; Hibi, Taizo; Yagi, Hiroshi; Abe, Yuta; Matsubara, Kentaro; Cho, Hakusyo; Wakayama, Yuko; Taniki, Nobuhito; Yamaguchi, Akihiro; Amemiya, Ryusuke; Miyake, Rei; Mizota, Takamasa; Kanai, Takanori; Kitagawa, Yuukou.
In: Hepatology Research, Vol. 46, No. 11, 01.10.2016, p. 1118-1128.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation
AU - Shinoda, Masahiro
AU - Ebinuma, Hirotoshi
AU - Itano, Osamu
AU - Yamagishi, Yoshiyuki
AU - Obara, Hideaki
AU - Kitago, Minoru
AU - Nakamoto, Nobuhiro
AU - Hibi, Taizo
AU - Yagi, Hiroshi
AU - Abe, Yuta
AU - Matsubara, Kentaro
AU - Cho, Hakusyo
AU - Wakayama, Yuko
AU - Taniki, Nobuhito
AU - Yamaguchi, Akihiro
AU - Amemiya, Ryusuke
AU - Miyake, Rei
AU - Mizota, Takamasa
AU - Kanai, Takanori
AU - Kitagawa, Yuukou
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Aim: Simeprevir (SMV) is a protease inhibitor which demonstrates good tolerability and high antiviral response in patients with hepatitis C. The clinical outcomes of triple therapy using simeprevir, pegylated interferon and ribavirin (SMV/PEG IFN/RBV) for recurrent hepatitis C after living donor liver transplantation (LDLT) have not been well reported. In this study, we assessed the outcomes of patients with recurrent hepatitis C (genotype 1) after LDLT who received triple therapy at our hospital. Methods: SMV/PEG IFN/RBV was administrated for 12 weeks (triple therapy), followed by another 12 weeks or extended period of PEG IFN/RBV (dual therapy). Virological response, interaction with calcineurin inhibitors and adverse events were retrospectively analyzed. Results: Ten patients with recurrent hepatitis C after LDLT completed 12 weeks of triple therapy. Nine patients achieved rapid or early virological response, and one patient was a non-responder. The nine responders received subsequent dual therapy, and the duration of dual therapy was extended (24 to 36 weeks) in five cases. Although one patient was in relapse 8 weeks after completing the standard duration (12 weeks) of dual therapy, eight patients achieved sustained virological response for 12 weeks (SVR12). The SVR12 rate was 80%. Trough levels of calcineurin inhibitor did not show marked changes after introduction of SMV in all cases. There were no major adverse events associated with SMV. Conclusion: SMV treatment may be a safe and effective option for recurrent hepatitis C after LDLT.
AB - Aim: Simeprevir (SMV) is a protease inhibitor which demonstrates good tolerability and high antiviral response in patients with hepatitis C. The clinical outcomes of triple therapy using simeprevir, pegylated interferon and ribavirin (SMV/PEG IFN/RBV) for recurrent hepatitis C after living donor liver transplantation (LDLT) have not been well reported. In this study, we assessed the outcomes of patients with recurrent hepatitis C (genotype 1) after LDLT who received triple therapy at our hospital. Methods: SMV/PEG IFN/RBV was administrated for 12 weeks (triple therapy), followed by another 12 weeks or extended period of PEG IFN/RBV (dual therapy). Virological response, interaction with calcineurin inhibitors and adverse events were retrospectively analyzed. Results: Ten patients with recurrent hepatitis C after LDLT completed 12 weeks of triple therapy. Nine patients achieved rapid or early virological response, and one patient was a non-responder. The nine responders received subsequent dual therapy, and the duration of dual therapy was extended (24 to 36 weeks) in five cases. Although one patient was in relapse 8 weeks after completing the standard duration (12 weeks) of dual therapy, eight patients achieved sustained virological response for 12 weeks (SVR12). The SVR12 rate was 80%. Trough levels of calcineurin inhibitor did not show marked changes after introduction of SMV in all cases. There were no major adverse events associated with SMV. Conclusion: SMV treatment may be a safe and effective option for recurrent hepatitis C after LDLT.
KW - calcineurin inhibitor
KW - direct-acting antiviral agent
KW - living donor liver transplantation
KW - recurrent hepatitis C
KW - simeprevir
KW - virological response
UR - http://www.scopus.com/inward/record.url?scp=84991112168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991112168&partnerID=8YFLogxK
U2 - 10.1111/hepr.12666
DO - 10.1111/hepr.12666
M3 - Article
C2 - 26854748
AN - SCOPUS:84991112168
VL - 46
SP - 1118
EP - 1128
JO - Hepatology Research
JF - Hepatology Research
SN - 1386-6346
IS - 11
ER -